MAP3K1 and invasive breast carcinoma: The high rate of MAP3K1 LoF mutations in ER-positive BrCa patients (frequently mPIK3CA) suggest that pathway cross-talk might be important in tumorigenesis or response to anti-cancer therapeutics.